STUDY: Ivermectin linked to “large reductions” in covid deaths

Casey Jones wrote:

Red Lily wrote:I don't know for sure 2.   I think @Casey Jones has posted info on it though.

I don't think Ivermectin is ever sold as a topical ointment.

What you can get, easily enough, is an oral equine paste.  Feed it to the horse...or to yourself or your kids.

If it were harmful, I'd have been dead six months ago.  Logically, it is not.  In practical experience, preppers, anti-mRNA stalwarts, and others here in the States have been using it, with some guidelines (not medical advice - the FDA tells us that it is HARMFUL to humans!).  So, DYODD.

In the charts available online, about 1.05 gram is a weekly dose for a 200-pound hominid.  I break that down into two half-gram doses.  Easy to do with the horse-applicator - it has a measuring tool on the plunger, a ring with stops, and notches.  I use three notches, Tuesday evening and Saturday morning.

Six months and I'm not sick.  Not proof; but it is proof that it won't kill you.

........... Ivermectin has been shown to inhibit the replication of SARS-CoV-2 in cell cultures.13 However, pharmacokinetic and pharmacodynamic studies suggest that achieving the plasma concentrations necessary for the antiviral efficacy detected in vitro would require administration of doses up to 100-fold higher than those approved for use in humans.14,15 Even though ivermectin appears to accumulate in the lung tissue, predicted systemic plasma and lung tissue concentrations are much lower than 2 µM, the half-maximal inhibitory concentration (IC50) against SARS-CoV-2 in vitro.16-19 Subcutaneous administration of ivermectin 400 µg/kg had no effect on SARS-CoV-2 viral loads in hamsters. However, there was a reduction in olfactory deficit (measured using a food-finding test) and a reduction in the interleukin (IL)-6:IL-10 ratio in lung tissues.20

Since the last revision of this section of the Guidelines, the results of several randomized trials and retrospective cohort studies of ivermectin use in patients with COVID-19 have been published in peer-reviewed journals or have been made available as manuscripts ahead of peer review. Some clinical studies showed no benefits or worsening of disease after ivermectin use,21-24 whereas others reported shorter time to resolution of disease manifestations that were attributed to COVID-19,25-27 greater reduction in inflammatory marker levels,26 shorter time to viral clearance,21 or lower mortality rates in patients who received ivermectin than in patients who received comparator drugs or placebo.21,27

However, most of these studies had incomplete information and significant methodological limitations, which make it difficult to exclude common causes of bias. These limitations include: ...................

Sprintcyclist wrote:

...........   Ivermectin has been shown to inhibit the replication of SARS-CoV-2 in cell cultures.13 However, pharmacokinetic and pharmacodynamic studies suggest that achieving the plasma concentrations necessary for the antiviral efficacy detected in vitro would require administration of doses up to 100-fold higher than those approved for use in humans.14,15 Even though ivermectin appears to accumulate in the lung tissue, predicted systemic plasma and lung tissue concentrations are much lower than 2 µM, the half-maximal inhibitory concentration (IC50) against SARS-CoV-2 in vitro.16-19 Subcutaneous administration of ivermectin 400 µg/kg had no effect on SARS-CoV-2 viral loads in hamsters. However, there was a reduction in olfactory deficit (measured using a food-finding test) and a reduction in the interleukin (IL)-6:IL-10 ratio in lung tissues.20

Since the last revision of this section of the Guidelines, the results of several randomized trials and retrospective cohort studies of ivermectin use in patients with COVID-19 have been published in peer-reviewed journals or have been made available as manuscripts ahead of peer review. Some clinical studies showed no benefits or worsening of disease after ivermectin use,21-24 whereas others reported shorter time to resolution of disease manifestations that were attributed to COVID-19,25-27 greater reduction in inflammatory marker levels,26 shorter time to viral clearance,21 or lower mortality rates in patients who received ivermectin than in patients who received comparator drugs or placebo.21,27

However, most of these studies had incomplete information and significant methodological limitations, which make it difficult to exclude common causes of bias. These limitations include:       ...................

https://www.covid19treatmentguidelines.nih.gov/therapies/antiviral-therapy/ivermectin/

It is not recommended.
That is what I make of it.